{"status":"OK","data":{"id":3130391,"identifier":"DVN/REVVTB","persistentUrl":"https://doi.org/10.7910/DVN/REVVTB","protocol":"doi","authority":"10.7910","publisher":"Harvard Dataverse","publicationDate":"2019-02-04","storageIdentifier":"s3://10.7910/DVN/REVVTB","latestVersion":{"id":134024,"storageIdentifier":"s3://10.7910/DVN/REVVTB","versionNumber":1,"versionMinorNumber":0,"versionState":"RELEASED","productionDate":"Production Date","lastUpdateTime":"2019-02-04T18:02:53Z","releaseTime":"2019-02-04T18:02:53Z","createTime":"2018-03-04T23:30:02Z","license":"CC0","termsOfUse":"CC0 Waiver","metadataBlocks":{"citation":{"displayName":"Citation Metadata","fields":[{"typeName":"title","multiple":false,"typeClass":"primitive","value":"Prion disease risk uncertainties associated with urine-derived and recombinant fertility drugs (Suppl. Figures S1-S26)"},{"typeName":"author","multiple":true,"typeClass":"compound","value":[{"authorName":{"typeName":"authorName","multiple":false,"typeClass":"primitive","value":"Cashman, Neil R. "},"authorAffiliation":{"typeName":"authorAffiliation","multiple":false,"typeClass":"primitive","value":"University of British Columbia"}}]},{"typeName":"datasetContact","multiple":true,"typeClass":"compound","value":[{"datasetContactName":{"typeName":"datasetContactName","multiple":false,"typeClass":"primitive","value":"Cashman, Neil R. "},"datasetContactAffiliation":{"typeName":"datasetContactAffiliation","multiple":false,"typeClass":"primitive","value":"University of British Columbia"},"datasetContactEmail":{"typeName":"datasetContactEmail","multiple":false,"typeClass":"primitive","value":"Neil.Cashman@vch.ca"}}]},{"typeName":"dsDescription","multiple":true,"typeClass":"compound","value":[{"dsDescriptionValue":{"typeName":"dsDescriptionValue","multiple":false,"typeClass":"primitive","value":"Supplementary Figures S1-S26  for citation: Cashman, N.R., Tyshenko, M.G., Cheung, R., Aspinall, W., Wong, M., and Krewski, D. (2018) ‘Prion disease risk uncertainties associated with urine-derived and recombinant fertility drugs’, Int. J. of Risk Assessment and Management,Vol. xy, No. yx, pp.xxx–yyy."},"dsDescriptionDate":{"typeName":"dsDescriptionDate","multiple":false,"typeClass":"primitive","value":"2018-03-04"}}]},{"typeName":"subject","multiple":true,"typeClass":"controlledVocabulary","value":["Medicine, Health and Life Sciences"]},{"typeName":"keyword","multiple":true,"typeClass":"compound","value":[{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"urine-derived fertility drugs"},"keywordVocabulary":{"typeName":"keywordVocabulary","multiple":false,"typeClass":"primitive","value":"urine-derived fertility drugs"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"recombinant fertility drugs"},"keywordVocabulary":{"typeName":"keywordVocabulary","multiple":false,"typeClass":"primitive","value":"recombinant fertility drugs"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"prions"},"keywordVocabulary":{"typeName":"keywordVocabulary","multiple":false,"typeClass":"primitive","value":"prions"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"expert elicitation"},"keywordVocabulary":{"typeName":"keywordVocabulary","multiple":false,"typeClass":"primitive","value":"expert elicitation"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"risk management"},"keywordVocabulary":{"typeName":"keywordVocabulary","multiple":false,"typeClass":"primitive","value":"risk management"}}]},{"typeName":"publication","multiple":true,"typeClass":"compound","value":[{"publicationCitation":{"typeName":"publicationCitation","multiple":false,"typeClass":"primitive","value":"Cashman, N.R., Tyshenko, M.G., Cheung, R., Aspinall, W., Wong, M., and Krewski, D. (2018) ‘Prion disease risk uncertainties associated with urine-derived and recombinant fertility drugs’, Int. J. of Risk Assessment and Management,Vol. xy, No. yx, pp.xxx–yyy."}}]},{"typeName":"depositor","multiple":false,"typeClass":"primitive","value":"Tyshenko, Michael G."},{"typeName":"dateOfDeposit","multiple":false,"typeClass":"primitive","value":"2018-03-04"}]}},"files":[{"description":"Figures S1-S26 provided show the experts’ responses as described, both individually and collectively.  For reach expert, the 5th and 95th percentiles denote their reported credible range, with the 50th percentile representing their central value judgment in response to these questions (the unweighted and weighted combinations of their individual opinions are designated by ‘Equal’ and ‘Perf’ in the figures).","label":"Suppl Figures S1-S26.docx","restricted":false,"version":1,"datasetVersionId":134024,"dataFile":{"id":3130392,"persistentId":"","pidURL":"","filename":"Suppl Figures S1-S26.docx","contentType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","filesize":970350,"description":"Figures S1-S26 provided show the experts’ responses as described, both individually and collectively.  For reach expert, the 5th and 95th percentiles denote their reported credible range, with the 50th percentile representing their central value judgment in response to these questions (the unweighted and weighted combinations of their individual opinions are designated by ‘Equal’ and ‘Perf’ in the figures).","storageIdentifier":"s3://dvn-cloud:161f34c677c-ea5477686506","rootDataFileId":-1,"md5":"615e051b5ea4aae967b9bd6742ce43be","checksum":{"type":"MD5","value":"615e051b5ea4aae967b9bd6742ce43be"}}}]}}}